

# PRODUCT INFORMATION



## Imlunestrant

Item No. 44974

**CAS Registry No.:** 2408840-26-4  
**Formal Name:** (5R)-5-[4-[2-[3-(fluoromethyl)-1-azetidiny]ethoxy]phenyl]-8-(trifluoromethyl)-H-[1]benzopyrano[4,3-c]quinolin-2-ol

**MF:** C<sub>29</sub>H<sub>24</sub>F<sub>4</sub>N<sub>2</sub>O<sub>3</sub>


**FW:** 524.5

**Purity:** ≥98%

**Supplied as:** A solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Imlunestrant is supplied as a solid. A stock solution may be made by dissolving the imlunestrant in the solvent of choice, which should be purged with an inert gas. Imlunestrant is soluble (≥10 mg/ml) in DMSO and ethanol.

### Description

Imlunestrant is a selective estrogen receptor degrader (SERD).<sup>1</sup> It induces degradation of wild-type ERα and ERα containing an activating tyrosine-to-serine mutation at residue 537 (ERα<sup>Y537S</sup>) when used at a concentration of 100 nM. Imlunestrant reduces growth of ER<sup>+</sup> T47D and MCF-7 breast cancer cells (IC<sub>50</sub>s = 0.34 and 5.2 nM, respectively) but not MDA-MB-231 triple-negative breast cancer cells. It also reduces growth of ERα<sup>Y537S</sup>-expressing T47D and MCF-7 cells (IC<sub>50</sub>s = 113 and 512 nM, respectively). Imlunestrant (15 mg/kg per day) induces tumor regression in an ERβ-independent, ERα<sup>Y537S</sup>-mutant-harboring liver metastasis patient-derived xenograft (PDX) model. Formulations containing imlunestrant have been used in the treatment of breast cancer.

### Reference

1. Sherman, S., Sandusky, Z. M., Russo, D., *et al.* Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor-positive breast cancer. *JCI Insight* **10(12)**, e188051 (2025).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/10/2026

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM